K lotho gene (KL, MIM604824) was first identified as an aging suppressor gene on the basis that two independent strains of KL-deficient mice manifest a syndrome resembling accelerated human aging, including muscle and skin atrophy, osteopenia, vascular, and soft tissue calcification, the resultant effect being a shorter life span (1) (2) (3) . Administration of soluble klotho protein in KL-deficient mice resulted in a greater median survival (4) . Furthermore, KL gene overexpression in transgenic mice extends life span (5) . In humans, a 13-year-old child was reported with a KL gene homozygote missense H193R mutation leading to protein destabilization and functional defects. Her phenotype associated marked hyperphosphatemia, hypercalcemia, and severe tumoral calcinosis with carotid artery calcifications (6) .
In mice, experimental chronic kidney disease (CKD) is associated with very low renal, plasma, and urinary levels of klotho, suggesting that CKD is a state of klotho deficiency (7) . Klotho-deficient mice with experimental CKD display highly calcified vessels, whereas klotho overexpression protects from CKDinduced vascular calcification (7) . Moreover, cardiac hypertrophy and fibrosis induced by experimental kidney disease in klotho-deficient mice are prevented by klotho overexpression (8) . Of importance, fibroblast growth factor (FGF)-23, which rises during CKD and possesses a direct cardiac toxicity, only exerts its noxious properties when serum klotho (seKL) is reduced (8) . All of these aforementioned abnormalities are present in CKD patients. Patients with CKD display decreased KL gene expression in several tissues, including the kidney. This results in reduced levels of circulating seKL. seKL is decreased in all stages of the disease, including early CKD (9, 10) , and in chronic dialysis (11, 12) . According to the CKD stage, seKL values are reduced by 40 to 60% (10, 13, 14) . Decreased vascular klotho gene expression and reduced seKL concentrations have been associated with the presence and severity of coronary artery disease independently of established cardiovascular (CV) risk factors (15, 16) . The relationship between serum phosphate and mortality is a matter of debate. Although significantly associated with mortality in very large cohorts of dialysis patients (17, 18) , the actual influence of elevated serum phosphorus is rather moderate, explaining mortality by 1 to 5% or increasing mortality by 10 to 20% for highly elevated serum phosphorus levels (19) . Collectively, these experimental and clinical observations may suggest an important weight of klotho metabolism on the highspeed aging and reduced life span reported in kidney patients. The ARNOGENE study was designed to prospectively follow a cohort of hemodialysis patients for 2 years and study the consequences of spontaneous klotho deficiency on CV events.
Materials and Methods

Patients
The ARNOGENE study was designed to prospectively follow a cohort of hemodialysis patients for 2 years and assess whether seKL was associated with CV events. The study analyzed data from the ARNOGENE prospective cohort settled in the Rhône-Alpes area in France. All 24 dialysis centers were asked to participate in the study. Sixteen centers accepted, and 856 prevalent hemodialysis patients were included between November 2008 and January 2009 (Fig. 1) . Informed consents were obtained and signed by all patients. Fifty-eight patients' records were not accessible for analysis, and analytical failure was observed in 555 measurements (described later). The remaining 238 patients formed the analyzed population, which was not different from the national population, as described in two previous French cohorts (19, 20) , except for age and diabetes frequency; all other data documented in Table 1 were similar. Patients were prospectively followed with clinical and biological assessments at 12-month intervals until January 2011. CV events and causes of death were systematically recorded. The number and cause of hospitalization were recorded on a yearly basis; however, the exact hospitalization Events CV events were assessed by each physician in charge of their patients based on a predetermined list of events: cardiac insufficiency based on altered ejection fraction, ischemic cardiopathy proven by coronarography or electrocardiogram or cardiologist assessment, stroke, and peripheral vascular disease, including vascular access failure. Other non-CV events included diabetes onset, kidney transplantation, and all other causes. Causes for hospitalization and deaths were classified as CV, non-CV, or unknown.
Circulating klotho and FGF-23 assays
Blood was drawn fasted before the start of the dialysis session. For transport purposes, serum was stored in two different batches, one at 280°C after collection (n = 238) and the other at 220°C for 6 months (n = 555), and then were moved to a 280°C freezer until measurements. Serum a-klotho was measured by enzyme-linked immunosorbent assay (IBL, Gunma, Japan; normal values 239 to 1266 ng/L). Intraindividual coefficient of variation was 4%. Undetectable seKL values were set at the threshold value for detection (117 ng/L). The different storage processes resulted in undetectable klotho value in many of the samples previously kept at 220°C for 6 months, because in this series, 65% of values were below the detection value, whereas in the samples fully kept at 280°C, there was no sample below the detection value. Thus, we decided to exclude from analysis all samples first stored at 220°C from analysis (see Fig. 1 ). Serum FGF-23 was measured by a quantitative sandwich enzyme-linked immunosorbent assay (Immutopics, Athens, OH; normal values: 34 to 96 RU/mL).
Other serum values were measured on a midweek day, in each facility's laboratory, as standard routine measurements.
Statistical methods
The main outcome was the 2-year CV event-free survival probability. It considered any CV event or death attributable to CV events as principal or secondary cause of death within the 2 years following inclusion.
Because we wanted to assess the effects of conserved seKL values, we chose to study serum values categorized to consider collectively the very low values in one category. For this purpose, a sensitivity analysis was made and showed that the risk trend was linear between seKL values comprised between 100 and 500 ng/L. We chose an empirical threshold at the first quartile of seKL distribution, i.e., 280 ng/L, which enabled us to identify a clinically significant number of patients. FGF-23 values were also categorized in quartiles. seKL levels were described in the population as well as main characteristics and known confounding prognostic variables (age, sex, dialysis vintage, presence of diabetes, cardiac insufficiency and serum hemoglobin, albumin, FGF-23, calcium, and phosphate). Continuous variables were summarized with median (range), and categorical variables with number and percentage. Two-year CV event-free survival was studied fitting binary logistic regression. Binary seKL were introduced in nonadjusted models as well as the main confounders cited previously. seKL was introduced in systematically adjusted models. All confounders cited previously were introduced in addition to seKL. The model included only patients for whom no variable was missing. Results were presented as odds ratio (OR) with 95% confidence interval (CI). Analyses were performed with R software (software 3.0.2, 2013; R Development Core Team; R: A Language Environment for Statistical Computing. Vienna, Austria; ISBN 3-900051-07-0. URL: www.R-project.org 2013).
Results Fig. 1 presents the flow of patients in the study and Table 1 seKL association with CV morbidity and mortality A total of 49 deaths occurred among the 238 patients from the cohort followed during 2 years. These included 18 deaths from CV origin and 31 deaths from non-CV origin. To further document the association of seKL with CV outcome, all hospitalizations for CV events were studied in addition to CV mortality. Among the 238 patients from the cohort, 48 patients presented with CV events within the 2-year follow-up, including the 18 CV deaths. The other available causes of events were as follows: 8 cardiac insufficiency episodes, 4 arrhythmias, 6 coronary events (myocardial infarction 1/unstable angina pectoris 5), and 18 events of vascular nature (peripheral vascular disease 14/stroke 4). To further highlight the competitive role of klotho/FGF-23 on CV events, we grouped patients by the first quartiles of klotho (,280 ng/L or $280 ng/L) and FGF-23 (, or $500 rU/mL) and distinguished three different groups: high seKL, low seKL/low FGF-23, and low seKL/high FGF-23 (Fig. 2) . Patients in the high klotho group had a trend for less CV events [ Fig. 2(a) ] and a better survival [ Fig. 2(b) ]. Interestingly, there was a trend for more CV events and impaired survival in the low klotho subgroup only when serum FGF-23 was high.
A nonadjusted logistic regression analysis showed a 61% lower probability of CV events in patients having a seKL .280 ng/L compared with lower levels of seKL [OR = 0.39 CI (0.20 to 0.78), P = 0.008] ( Table 2) . Age, cardiac insufficiency, serum FGF-23, and serum albumin were associated with CV events as well. After adjustment, the occurrence of CV events in patients with a higher seKL was still present [OR = 0.86 CI (0.76 to 0.99), P = 0.030]. Whereas cardiac insufficiency and serum FGF-23 were still independent predictors of CV events, age and serum albumin were not associated with CV events anymore ( Table 2) . After adjustment, serum FGF-23 was significantly associated with CV events [OR = 1.07 CI (1.02 to 1.13), P = 0.005] ( Table 2) , however with a lower magnitude compared with seKL (OR 1.07 vs 0.86). Serum calcium and phosphate were not significantly associated with CV events, before or after adjustment.
Discussion
In the current study, we report a clear association between reduced CV morbidity and mortality during chronic hemodialysis and preserved seKL ( Table 2) . Our first observation is the documentation of a low level of seKL, lower than in patients experiencing mild CKD without need for dialysis treatment (10) . Indeed, the present median klotho is 360 (IQR 176) ng/L, ;57% of values observed in the Health Aging and Body Composition Study [median 630 (IQR 160) ng/L], in which the mean glomerular filtration rate (GFR) was already reduced, e.g., 73 mL/min (13) . In a previous report, we showed that patients with a GFR of 71 mL/min had a mean seKL value of 478 (IQR 130) ng/L (10). In healthy adults, seKL has been reported to be 845 6 330 ng/L (14) . Animal and human studies identified CKD as a state of klotho deficiency (7, 10) . The expression of klotho gene is reduced in the diseased kidney (7, 21) and in CKD animals (7, 22) . Patients under chronic hemodialysis have reduced klotho protein in their kidneys (23) . Reasons for low seKL levels during CKD are poorly understood but may result from the defective klotho secretion in the diseased kidney. A selective nephron klotho knockdown in mice reduces seKL by 80% (24) , revealing the kidney as the principal contributor of circulating klotho (24) . CKD metabolic alterations such as increased proteinuria or metabolic acidosis may contribute to reduce nephron klotho synthesis (10) . In the current study, patients with detectable levels had a median seKL of 360.4 ng/L (IQR 176.5 ng/L). These values are further reduced by ;25% as compared with CKD patients presenting with a mild kidney disease (mean GFR, 70 mL/min) and a median seKL of 478 ng/L (10), and markedly reduced as compared with a normal renal function adult population (13, 14) . To date, this pathophysiological abnormality has not been reported in other human conditions apart from the exceptional report of homozygote missense mutations in KL gene (6) .
A previous study in 227 maintenance hemodialysis patients from Nowak et al. (25) failed to show an association of circulating klotho with mortality in a multivariable adjusted analysis when klotho was examined either on a continuous scale [hazard ratio (HR) 1.25 per standard deviation increase, 95% CI 0.84 to 1.86] or in tertiles, with tertile 1 as the reference category [HR for tertile two 0.65 (0.26 to 1.64) and for tertile three 2.18 (0.91 to 2.23)] (25) . This study may have suffered from insufficient power because only 40 events were registered at 2 years, and CV morbidity and mortality were not recorded. Nevertheless, the authors found that higher seKL levels were associated with the absence of atrial fibrillation (HR 0.66 per standard deviation increase, 95% CI 0.41 to 1.00). These experimental and clinical data are therefore in support of a direct cardioprotective effect of seKL, independent from phosphate metabolism, and provide credit to our findings.
Klotho is expressed as a cell membrane protein or cleaved as a secreted protein present in plasma that exerts both paracrine and endocrine functions (5) . Both the fulllength and the extracellular domain of klotho protein are able to bind FGF receptors (26) and act as a cofactor for FGF-23. Klotho gene knockout animals express increased serum phosphate as a consequence of a sustained action of NaPi2 cotransporter; indeed, hyperphosphatemia is corrected in a double-knockout mouse for klotho plus for the renal phosphate transporter NaPi 2 (27) . Thus, a combined klotho deficiency and sustained dietary phosphate exposure may partly explain the resistant hyperphosphatemia frequently observed in CKD. Therefore, klotho deficiency may be partly responsible for the CV morbidity and mortality secondary to the CKD-altered phosphate and calcium metabolism. Additionally, circulating klotho was recently shown to provide protection against uremic cardiomyopathy (28) and improve uremic remodelling (8) . A CKD model induced in heterozygote KL gene knockout mice resulted in barely detectable levels of circulating klotho and in a cardiomyopathy with a rapid installation of cardiac hypertrophy and fibrosis (28) . These features were significantly milder in the wild-type KL +/+ CKD mice. Furthermore, cardiomyopathy in klotho-deficient CKD mice was improved following administration of a transgene encoding klotho (28) .
The current study did not confirm serum phosphorus as a determinant for CV events. By introducing phosphorus in adjusted analyses, not only this did not change the effect size of the covariates, including seKL, indicating that its confounding effect is weak, but its own OR on CV events remained nonsignificant (P = 0.25; Table 2 ).
In our multivariable analysis, circulating FGF-23 remained an independent factor of CV event, besides seKL, although to a lesser extent (Table 2) . Prospective observational studies have shown that serum FGF-23 concentrations predict mortality not only among dialysis patients but among predialysis CKD patients as well (29) . Raised FGF-23 levels were associated with CV events and mortality in CKD patients (30, 31) and with increased all-cause mortality in hemodialysis patients (32) . Our results suggest that elevated FGF-23 levels remain detrimental independently from klotho deficiency ( Table 2) . Fig. 2 suggests that a high seKL is associated with less CV events [ Fig. 2(a) ] and survival [ Fig. 2(b) ] whatever the FGF-23 level, whereas patients having a low seKL have a trend to more CV events and worse survival only when FGF-23 is elevated. However, due to a very limited number of events in these subgroups, such results should be confirmed in a larger study. Increasing seKL therapeutically might directly improve cardiomyopathy and indirectly blunt the cardiotoxic FGF-23 effects, as suggested by Xie et al. (28) .
There are limitations to our study, which include the relatively small size of the study, the French origin of dialysis population, with less overweighed patients, reduced diabetes frequency, and more smokers than in North American cohorts, and therefore these results may not be generalized.
Conclusion
We therefore show that chronic hemodialysis patients with a preserved level of seKL display a 14% decreased probability of CV events at 2-year follow-up, after accounting for main confounders (P = 0.03). Thus, a preserved klotho function supports CV protection and may represent a prognostic tool and therapeutic target for CV disease.
